Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114625 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL6114605 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL6115189 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL6114660 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL6115263 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL6114969 | 1.00 | TRPV1 (0.58) | TRPV1PDE10ATLR8CYP1A2TLR7 | |
| SCHEMBL859430 | 0.98 | TRPV1 (0.56) | TRPV1PDE10ATLR8CYP1A2MEN1 | |
| SCHEMBL6114503 | 0.93 | PDE10A (0.60) | TRPV1PDE10ATLR8CYP1A2MEN1 | |
| SCHEMBL11597016 | 0.92 | CYP1A2 (0.50) | TRPV1PDE10ACYP1A2 | |
| SCHEMBL6115113 | 0.86 | TRPV1 (0.55) | TRPV1PDE10ACYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821395-A2 | Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery | Wako Pure Chemical Industries, Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8716513-B2 | Process for production of bis-quaternary ammonium salt, and novel intermediate | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2463266-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | ASS1, C1S, FHIT | TRPV1 2435/4885PDE10A 3929/4885TLR8 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.